Olux E patents expiration

OLUX E's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000 MYLAN Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(1 year, 11 months from now)

US8460641 MYLAN Microemulsion process and composition
Nov, 2028

(5 years from now)

Olux E is owned by Mylan.

Olux E contains Clobetasol Propionate.

Olux E has a total of 2 drug patents out of which 0 drug patents have expired.

Olux E was authorised for market use on 12 January, 2007.

Olux E is available in aerosol, foam;topical dosage forms.

Olux E can be used as treatment of corticosteroid-responsive dermatoses.

The generics of Olux E are possible to be released after 05 November, 2028.

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 12 January, 2007

Treatment: Treatment of corticosteroid-responsive dermatoses


How can I launch a generic of OLUX E before it's drug patent expiration?
More Information on Dosage

OLUX E family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic